| VIS ID | Virus | Ensembl ID | Gene Type | Target Gene | Oncogene | Tumor Suppressor Gene | NCBI ID | Uniprot ID |
|---|---|---|---|---|---|---|---|---|
| TVIS10062353 | HBV | ENSG00000160200.18 | protein_coding | CBS | No | No | 875 | P35520 |
| TVIS10062354 | HBV | ENSG00000160200.18 | protein_coding | CBS | No | No | 875 | P35520 |
Target Gene Table
▼
TCGA Plot Options
▼
Drug Information
▼
| Gene | CBS |
|---|---|
| DrugBank ID | DB00133 |
| Drug Name | Serine |
| Target ID | BE0000323 |
| UniProt ID | P35520 |
| Regulation Type | |
| PubMed IDs | 17352495; 17629356 |
| Citations | Sen S, Banerjee R: A pathogenic linked mutation in the catalytic core of human cystathionine beta-synthase disrupts allosteric regulation and allows kinetic characterization of a full-length dimer. Biochemistry. 2007 Apr 3;46(13):4110-6. Epub 2007 Mar 13.@@Qu K, Lee SW, Bian JS, Low CM, Wong PT: Hydrogen sulfide: neurochemistry and neurobiology. Neurochem Int. 2008 Jan;52(1-2):155-65. Epub 2007 Jun 8. |
| Groups | Investigational; Nutraceutical |
| Direct Classification | Serine and derivatives |
| SMILES | N[C@@H](CO)C(O)=O |
| Pathways | Phosphatidylethanolamine Biosynthesis PE(15:0/18:1(11Z)); Phosphatidylethanolamine Biosynthesis PE(14:0/22:2(13Z,16Z)); Phosphatidylethanolamine Biosynthesis PE(14:1(9Z)/18:1(9Z)); Phosphatidylethanolamine Biosynthesis PE(14:0/24:1(15Z)); Phosphatidylethanolamine Biosynthesis PE(15:0/18:0); Phosphatidylethanolamine Biosynthesis PE(14:0/18:1(9Z)); Phosphatidylethanolamine Biosynthesis PE(14:1(9Z)/24:0); Phosphatidylethanolamine Biosynthesis PE(14:1(9Z)/20:3(8Z,11Z,14Z)); Phosphatidylethanolamine Biosynthesis PE(15:0/14:0); Phosphatidylethanolamine Biosynthesis PE(14:0/22:1(13Z)); Phosphatidylethanolamine Biosynthesis PE(14:0/18:1(11Z)); Phosphatidylethanolamine Biosynthesis PE(14:1(9Z)/18:3(9Z,12Z,15Z)); Phosphatidylethanolamine Biosynthesis PE(14:1(9Z)/14:1(9Z)); Phosphatidylethanolamine Biosynthesis PE(15:0/15:0); Phosphatidylethanolamine Biosynthesis PE(14:0/14:1(9Z)); Glycine and Serine Metabolism; Phosphatidylethanolamine Biosynthesis PE(14:0/20:4(8Z,11Z,14Z,17Z)); Phosphatidylethanolamine Biosynthesis PE(15:0/16:0); Selenoamino Acid Metabolism; Phosphatidylethanolamine Biosynthesis PE(14:1(9Z)/22:5(4Z,7Z,10Z,13Z,16Z)); Phosphatidylethanolamine Biosynthesis PE(14:0/15:0); Phosphatidylethanolamine Biosynthesis PE(14:1(9Z)/20:4(8Z,11Z,14Z,17Z)); Phosphatidylethanolamine Biosynthesis PE(14:1(9Z)/18:3(6Z,9Z,12Z)); Cystathionine beta-Synthase Deficiency; Sarcosine Oncometabolite Pathway; Phosphatidylethanolamine Biosynthesis PE(14:1(9Z)/20:0); Phosphatidylethanolamine Biosynthesis PE(14:0/14:0); Globoid Cell Leukodystrophy; Phosphatidylethanolamine Biosynthesis PE(15:0/18:1(9Z)); Ammonia Recycling |
| PharmGKB | PA451330 |
| ChEMBL | CHEMBL11298 |
